SIK3 and ovarian carcinoma: In our cohort, we observed that most of the patients with high expression levels of SIK3 and CA125 had stage III disease (45.6% for SIK3 and 67.3% for CA125) and serous-type ovarian cancer (46.8% for SIK3 and 70.1% for CA125).